INDICATION

EPCLUSA (sofosbuvir 400 mg/velpatasvir 100 mg, 200 mg/50 mg tablets; 200 mg/50 mg, 150 mg/37.5 mg oral pellets) is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1-6 infection without cirrhosis or with compensated cirrhosis.

DIAGNOSE AND START THE JOURNEY TO HELP CURE CHRONIC HCV1

>4 million

people living in United States with HCV, only 5% treated2,3,a

aBased on NHANES+ model estimates of current HCV infections from 2017-2020 and AASLD treatment numbers from 2020.2,3

1 in 2 people

who inject drugs in the United States have HCV4,b

b45% of people 17-35 years of age.4

Within the first 3 years of initial infection

Each person with HCV who injects drugs is likely to infect ~20 people5,c

Within the first 3 years of initial infection, each person with HCV who injects drugs is likely to infect ~20 people

cBased on the 2021 NIH National Institute on Drug Abuse Heroin Research Project.5

Within the first 3 years of initial infection, each person with HCV who injects drugs is likely to infect ~20 people

GUIDELINES RECOMMEND UNIVERSAL TESTING AND TREATMENT FOR HEPATITIS C, INCLUDING IN PEOPLE WHO INJECT DRUGS6-8

Test All Adult Patients
At Least Once
Test All At-Risk
Patients
Begin Treating All
Diagnosed Patients
AASLD/IDSA

Check mark in circle icon

Check mark in circle icon

Check mark in circle icond

CDC

Check mark in circle icone

Check mark in circle icon

Check mark in circle iconf
USPSTF

Check mark in circle icong

Check mark in circle icon

Check mark in circle iconh

d Unless they have limited life expectancy that cannot be remediated by HCV treatment, liver transplantation, or another directed therapy.6

e Except in settings where the prevalence of HCV infection (HCV RNA-positivity) is <0.1%.7

f Patients need further evaluation before treatment.7

g Recommendations for screening of adults (18-79 years).8

h Adults with a positive result are usually followed up with a diagnostic evaluation8